Lien ville-–hôpital et anticancéreux oraux : opinion des pharmaciens de l’Aveyron

Cavallier, Guillaume; Laudet, Murielle; Vayssettes, Pierre-Marie; Balayssac, David; Chennell, Philip

doi:10.1016/j.bulcan.2022.02.007

Cited by 4 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In France, to secure a path for patients to receive oral anticancer therapy, Rubira et al reported the usefulness of a computerised tool for standardising information exchanged between ambulatory and hospital pharmacists. Conversely, insufficient communication between hospital and community pharmacies indicated that community pharmacists perceived problems in providing oral antineoplastic drugs (Cavallier et al, 2022 ). In the United States and the United Kingdom, an initiative called Collaborative Drug Therapy Management (CDTM) has been implemented with some success.…”

Section: Discussionmentioning

confidence: 99%

Survey of community and hospital pharmacist involvement in outpatient chemotherapy using Japanese health information data

Iwata,

Maezawa,

Miyasaka

et al. 2024

Journal of Pharmaceutical Policy and Practice

View full text Add to dashboard Cite

In this study, information on injectable anticancer drug use and additional fee for enhanced collaboration (AEC) and additional fee for specific drug management guidance 2 (ASD2) claims from the NDB Open Data Japan (NODJ) dataset and the number of patients with cancer according to sex and age from the National Cancer Registry (NCR) dataset were integrated and evaluated to determine the current status and challenges in pharmacist interventions for patients receiving cancer treatment. The NODJ data, including receipt data billed from 2020 to 2021, were obtained from the Ministry of Health, Labour and Welfare website. The use of injectable anticancer drugs decreased relative to the number of cancer patients aged ≥ 75 years compared to those aged < 75 years. Regarding injectable anticancer drug use, the number of AEC claims was similar between men and women, but the number of ASD2 claims was lower in men than in women. The number of times community pharmacists claimed their ASD2 was approximately 5% of the number of times hospital pharmacists claimed their AEC. This study revealed that several patients did not receive sufficient guidance from community pharmacists compared to hospital pharmacists, suggesting a potential insufficiency in the collaboration between the two groups.

show abstract

Section: Discussionmentioning

confidence: 99%